Results - Financial year ended 31/03/2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.0 pts more than Nifty Microcap 250 and 5.1 pts more than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medico Intercontinental reported strong FY25 standalone results with revenue from operations rising about 52% to ₹6,712.58 lakhs (vs ₹4,403.68 lakhs in FY24), driven mainly by stock-in-trade purchases. Standalone profit after tax grew roughly 35% to ₹256.58 lakhs (vs ₹189.70 lakhs), with EPS at ₹2.57 (vs ₹1.90). On a consolidated basis, however, revenue from operations actually fell about 21.5% to ₹5,601.52 lakhs, even as consolidated PAT rose around 28% to ₹505.73 lakhs, helped by subsidiaries Evagrace Pharma, Ritz Formulations, Sungrace Pharma, Azillian Healthcare and JV Medico Lab. The board also appointed Agarwal & Mehta as Secretarial Auditor for 5 years and re-appointed MJV & Co as Internal Auditor. The statutory auditor V. Goswami & Co issued an unmodified (clean) opinion on both sets of results, and long-term borrowings rose sharply from ₹186.97 lakhs to ₹1,347.25 lakhs on a consolidated basis.
Clean audit and strong profit growth are positives, but the sharp fall in consolidated top line despite higher profit suggests a shift in business mix or lower contribution from subsidiaries. The steep increase in long-term debt and major rise in trade receivables will be watched closely by investors.